Skip to main
HCAT

HCAT Stock Forecast & Price Target

HCAT Analyst Ratings

Based on 9 analyst ratings
Hold
Strong Buy 11%
Buy 11%
Hold 78%
Sell 0%
Strong Sell 0%

Bulls say

Health Catalyst is a leader in helping healthcare providers address and reduce spending waste, improve efficiency, and close gaps in care. With a strong focus on data and analytics technology, the company offers a customizable modular framework and professional services to help providers deliver measurable improvements in clinical, financial, and operational outcomes. The company has a large addressable market and a strong track record of success, making it a sound investment for those looking to capitalize on the growing demand for healthcare solutions.

Bears say

Health Catalyst is facing several challenges, including a challenging end market, negative mix shift, and potential customer loss that could affect their financials. With a longer sales cycle and increased competition in the healthcare data and analytics industry, there is a risk to the company's profitability and ability to grow. The potential divestiture of assets could create shareholder value, but a lack of transparency and guidance makes it difficult to accurately predict the company's future performance. The stock is currently trading at a discount to its peers, and while there may be opportunities for growth with a more efficient and aligned organization, executing on this without sufficient resources and a depressed stock price presents challenges.

HCAT has been analyzed by 9 analysts, with a consensus rating of Hold. 11% of analysts recommend a Strong Buy, 11% recommend Buy, 78% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Health Catalyst Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Health Catalyst Inc (HCAT) Forecast

Analysts have given HCAT a Hold based on their latest research and market trends.

According to 9 analysts, HCAT has a Hold consensus rating as of Jun 3, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $2.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $2.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Health Catalyst Inc (HCAT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.